ImmunGene inks agreement with Cephalon Australia
As per the terms of the agreement, ImmunGene is entitled to get undisclosed fees which include upfront payment from Cephalon Australia a four-year option to leverage ImmunGene’s novel
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.